Business
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen6{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnml40{\nMARGIN-LEFT:3.33em\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n \n \n \n \n \n \n PR Newswire\n \n \n \n \n \n Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented\n \n \n \n \n LAVAL, Quebec\n \n ,\n \n Oct. 25, 2021\n \n /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (\"Bausch Health\") and its gastroenterology business, Salix Pharmaceuticals, (\"Salix\"), one of the largest specialty pharmaceutical companies in the world committed to the treatment of gastrointestinal (GI) diseases and conditions, today announced seven posters featuring new data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) are being presented at the\n \n American College of Gastroenterology® (ACG) 2021 Annual Scientific Meeting\n \n , which is taking place\n \n Oct. 22-27, 2021\n \n in\n \n Las Vegas\n \n .\n \n \n \"Salix is pleased to present important new clinical data on three key products in our gastrointestinal portfolio at ACG's annual scientific meeting,\" said\n \n Robert Spurr\n \n , president, Salix Pharmaceuticals. \"We are especially excited to have the opportunity to connect in person with the gastroenterology community to col...